WT
Highly rated in
35
conditions
Highly rated in
35
conditions
Check Dr. William D. Tap's experience treating your condition:
About Dr. William D. Tap

William Tap is a Hematologist Oncology expert in New York, New York. Tap has been practicing medicine for over 22 years and is highly rated in 35 conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Epithelioid Sarcoma, Tissue Biopsy, and Liver Embolization. He is licensed to treat patients in New York and California. Tap is currently accepting new patients.

His clinical research consists of co-authoring 176 peer reviewed articles and participating in 16 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. William D. Tap it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. William D. Tap accepts the following insurance:

  •  Ambetter
Locations
1275 York Ave, New York, NY 10065
Background & Education
Graduate Institution
Jefferson Medical College Of Thomas Jefferson University, 2000
Specialties
Hematology Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
Memorial Sloan Kettering Cancer Center
Shore Medical Center
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


14 Clinical Trials

Phase II Study of Niraparib in Soft Tissue Sarcoma Patients With Altered DNA Damage Repair
A Phase 2 Study of Temsirolimus (CCI-779, NSC 683864) and IGF-1 Receptor Antibody Cixutumumab (IMC-A12, NSC 742460) in Patients With Metastatic Sarcomas
Phase II Trial Of Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
A Phase IB/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
A Phase Ib/II Study of BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
A Phase 1b Study of LY3039478 in Combination With Other Anticancer Agents in Patients With Advanced or Metastatic Solid Tumors
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Phase II Trial of Sorafenib and Dacarbazine in Soft Tissue Sarcoma
A Phase II Study of Sorafenib and Ifosfamide as a Treatment for Patients With Sarcoma
View 13 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors